{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-018988","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2022-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.073068+00:00","generated_at":"2026-06-23T06:46:42.539899+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galecto reports GB2064 reduces bone marrow fibrosis in 4 of 5 evaluable myelofibrosis patients","bullets":["Four of five evaluable patients on GB2064 achieved ≥1-grade reduction in collagen fibrosis over 6 months.","All four fibrosis responders showed stable hemoglobin, WBC, platelets, and spleen volume; no transfusions needed.","Two patients entered extension phase due to clinical benefit as assessed by treating physician.","No treatment-related SAEs in the 5-patient evaluable group; one possible SAE (fall) in entire 16-patient trial.","Company expects top-line results from GULLIVER-2 liver cirrhosis trial in coming weeks."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-018988","json":"https://secwatch.observer/filing/0000950170-22-018988.json","markdown":"https://secwatch.observer/filing/0000950170-22-018988.md","text":"https://secwatch.observer/filing/0000950170-22-018988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000095017022018988/0000950170-22-018988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000095017022018988/glto-20220929.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:46:42.539899+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}